Mentioned:
There’s a new drug development acquisition in the public markets. And it’s aiming to change the future of treating obesity and smoking cessation.
What’s happening:
- MIRA Pharmaceuticals (NASDAQ: MIRA) has officially announced they have entered into a binding deal to acquire biotechnology company SKNY Pharmaceuticals
Why it matters:
- SKNY Pharmaceuticals is developing a novel compound known as SKNY-1 which targets both weight loss and smoking cessation by interacting with cannabinoid receptors that regulate appetite, energy and metabolism
Going deeper:
- The acquisition of SKNY Pharmaceuticals will inject $5M USD in cash or assets into MIRA Pharmaceuticals upon closing
- MIRA Pharmaceuticals previously saw highly promising clinical data from their novel oral ketamine analogue therapeutic known as Ketamir-2, which they are advancing into human trials to treat neuropathic pain
